Log In
Print this Print this


Also known as: PXT-3003

  Manage Alerts
Collapse Summary General Information
Company Pharnext S.A.S.
DescriptionLow-dose combination of baclofen, naltrexone and sorbitol
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationNeuropathy
Indication DetailsTreat Charcot-Marie-Tooth Type IA (CMT1A) disease
Regulatory Designation U.S. - Orphan Drug (Treat Charcot-Marie-Tooth Type IA (CMT1A) disease);
EU - Orphan Drug (Treat Charcot-Marie-Tooth Type IA (CMT1A) disease)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today